Skip to main content

Table 2 Summary of diagnostic characteristics of AML.

From: Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study

Variable

Total

(n = 95)

AML ICU Cases

(n = 45)

AML non-ICU Controls

(n = 50)

p-value

AML WHO classification (n = 91)

    

   AML with recurrent genetic abnormalities

44 (46.3)

19 (42.2)

25 (50.0)

0.18

   AML with multi-lineage dysplasia

17 (17.9)

10 (22.2)

7 (14.0)

 

   AML and myelodysplastic syndromes, therapy-related

6 (6.3)

5 (11.1)

1 (2.0)

 

   AML not otherwise categorized

28 (29.5)

11 (24.4)

17 (34.0)

 

AML FAB Classification (n = 71)

    

   M0

4 (4.2)

0 (0)

4 (8.0)

0.12

   M1

28 (29.5)

15 (33.3)

13 (26.0)

 

   M2

20 (21.1)

11 (24.4)

9 (18.0)

 

   M3

12 (12.6)

3 (6.7)

9 (18.0)

 

   M4

12 (12.6)

4 (8.9)

8 (16.0)

 

   M4eo

5 (5.3)

4 (8.9)

1 (2.0)

 

   M5

13 (13.7)

7 (15.6)

6 (12.0)

 

   M6

1 (1.1)

1 (2.2)

0 (0)

 

Cytogenetic prognosis § (%)

    

   Good

13 (13.7)

6 (13.3)

7 (14.0)

0.96

   Intermediate

38 (40.0)

17 (37.8)

21 (42.0)

 

   Poor

14 (28.0)

13 (28.9)

14 (28.0)

 

   Unknown/not available

8 (16.0)

9 (20.0)

8 (16.0)

 

Complete blood count at diagnosis:

    

   Hemoglobin (g/L)

96.7 (22.1)

95.9 (21.6)

97.3 22.6)

0.76

   Platelets (cells/109)

46 (26-96)

45 (31-96)

47 (24-96)

0.46

White cell count (WBC) (cells/10 9 )

8.2 (2.3-50.6)

7.7 (2.0-50.8)

16.0 (3.2-42.9)

0.87

   WBC < 1 (%)

6 (7.1)

3 (6.7)

3 (6.0)

1.0

   WBC > 25 (%)

34 (35.8)

15 (33.3)

19 (38.0)

0.67

Duration of Neutropenia (days) (mean [SD])

14.1 (14.3)

13.1 (14.4)

15.2 (14.2)

0.48

Bone marrow blast count (%)

56.6 (23.7)

52.9 (23.7)

60.1 (23.5)

0.15

   Blasts >20%

86 (94.5)

41 (93.2)

45 (95.7)

0.67

AML Status

    

   Newly diagnosed/active disease

58 (61.1)

24 (53.3)

34 (68.0)

0.01

   Refractory/relapse

29 (30.5)

13 (28.9)

16 (32.0)

 

   BMT/remission

4 (4.2)

4 (8.9)

0 (0)

 

   Remission

4 (4.2)

4 (8.9)

0 (0)

 

Therapeutic Regimen

    

   Intensive/induction chemotherapy

78 (82.1)

38 (84.4)

40 (80.0)

0.60

   Cytoreductive/palliative

17 (17.9)

7 (15.6)

10 (20.0)

 
  1. Abbreviations: WHO = World Health Organization; FAB = French American British; WBC = white blood cell count
  2. § Cytogenetic Prognosis: Good = t(8;21); t(15;17); inv16 or t(16;16); Intermediate = normal; trisomy 8; 11q23 abnormality; Poor = deletion of chromosome 5 or 5q; deletion of chromosome 7 or 7q; 3q abnormality; complex; Unknown = significance not known; no cytogenetic information.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us